[-] Show simple item record

dc.contributor.authorRichmond, John R.eng
dc.contributor.authorBabcock, Chad F.eng
dc.contributor.authorMayo, Helen G.eng
dc.date.issued2004-06eng
dc.description.abstractBoth β2-agonists and anticholinergics appear to improve symptoms for patients with chronic obstructive pulmonary disease (COPD). Recent research indicates that adding a long-acting anti-cholinergic to a β2-agonist may improve quality of life for patients with stable COPD more than the use of β2-agonists alone. Both drug classes increase exercise capacity and alleviate symptoms of COPD, although neither alters disease progression (strength of recommendation [SOR]: A). Combination therapy can lead to greater improvements in forced expiratory volume in 1 second (FEV1) than either drug alone (SOR: A). However, until recently there were no convincing direct head-to-head comparisons of the 2 classes, and it is unclear whether this difference is clinically significant.eng
dc.identifier.citationJournal of Family Practice, 53(6) 2004: 494-496.eng
dc.identifier.urihttp://hdl.handle.net/10355/3016eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2004 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.subjectdisease progressioneng
dc.subjectquality of lifeeng
dc.subjectchronic obstructive pulmonary disease (COPD)eng
dc.subjectcombination therapyeng
dc.subject.lcshLungs -- Diseases, Obstructiveeng
dc.subject.lcshPulmonary Disease, Chronic Obstructiveeng
dc.subject.lcshAdrenergic beta agonistseng
dc.titleAre beta-2-agonists or anticholinergics more effective for treating COPD?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record